Jefferies gives Endo a buy rating

Endo Pharmaceuticals Holdings, Inc. was rated by Jefferies & Co., Inc., analyst David Windley at buy with a $35 price target. Jefferies expects a favorable Food and Drug Administration decision on oxymorphone (PDUFA date: June 22). Endo presented detailed efficacy and safety data on oxymorphone ER and oxymorphone IR at the 25th Annual American Pain Society meeting in San Antonio. Shares of the Chadds Ford, Pa., pharmaceutical company were down 6 cents, or 0.19%, at $31.72 on volume of 1,426,016 shares versus the three-month running average of 1,254,910 shares. (Nasdaq: ENDP)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.